“He was instrumental in getting the transaction across the line.”
Chambers USA 2025
“Eric is great and knows his stuff inside and out.”
Chambers USA 2025
"Eric is tremendously capable."
Chambers USA 2024
"Gives great legal advice and is super user-friendly."
Chambers USA 2024
Up-and-Coming – Derivatives
Chambers USA 2024
"He has demonstrated outstanding responsibility and commitment to support us on executing complex transactions within deadlines."
Chambers USA 2022
"He is super responsive and smart."
Chambers USA 2021
"He is able to make appropriate judgements and balance urgency and risk."
Chambers USA 2021
Profile
Eric Rice advises financial institutions, public companies, buy-side firms, and ultra-high-net-worth individuals on equity derivatives and equity-linked products.
Eric leverages his commercial perspective and pragmatism to structure and negotiate:
Hedging and monetization transactions, including more than US$50 billion notional amount in forward-sale transactions
Margin loans and other equity-based financing transactions
Convertible debt and equity and related derivative overlays
Structured acquisition and share repurchase transactions
Eric served as a law clerk to Judge David J. Barron on the US Court of Appeals for the First Circuit and holds an advanced degree in computer science.
Experience
Eric’s experience includes advising:
Financial institutions including Goldman, JPMorgan, Morgan Stanley, Citi, and Deutsche Bank as dealers on all manner of equity derivatives transactions and lenders in margin financing transactions
Private equity sponsors, founders, and other major shareholders as derivative end-users and margin loan borrowers
Apollo, Highbridge, and other investment management firms on bespoke convertible note and convertible preferred equity investments
Penguin Solutions, Amkor Technology, BridgeBio, Voyager Technologies, and other issuers on convertible securities issuances and related derivatives transactions
Two wins and seven finalist honors in the NYLJ’s annual awards program — including for Large Law Firm of the Year — reflect the firm’s litigation, transactional, and regulatory prowess, innovative office and practice leadership, and clear market leadership in New York.
Firm practice leaders and initiatives shortlisted for recognition across an array of categories for innovations related to dealmaking, regulatory, and training technology.
Firm’s Capital Markets Practice once again earns top legal advisor league table rankings across debt and equity products and industries globally in Bloomberg, Dealogic, Deal Point Data, and LSEG.
Multidisciplinary team represents the leading biotech in the investment with unicorn life sciences investors Sixth Street Partners and Healthcare Royalty, a business of KKR, to fund BridgeBio’s life-saving medicines for genetic disorders.
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.